explore -WSS

explore

author：entertainment 2025-09-28 23:11:07 - browse：16727

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Who are the detained American citizens released from prison in Iran?

WSS

TikTok, Instagram influencers need more rules for drug ads

Some of the ways extreme heat will change life as we know it

Target recalls 2.2 million additional candles due to laceration, burn hazards

Maui funeral service workers on devastation of fires: 'I'm in shock'

The history of OxyContin, told through Purdue Pharma documents

There's an unseen cost to disruptive road

Wikipedia

explore

entertainment

Jerome Adams on the need for new antivirals for Covid

Cardiologists urge adding sexual orientation, gender identity to health records

Apple is now the first public company to be valued at $3 trillion

Inaction leaves children at risk from dangerous chemotherapy drug

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA sets aggressive timeline for overhauling inspection procedures

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pumping milk in bathrooms at health conferences is common

In age of alternative facts, a scholarly course on calling out crap

Mass General, Mayo Clinic look to monetize custom

focus

Where are patients getting their prescriptions for GLP

Flu vaccine reformulation won't be easy, manufacturers warn

GOP presidential candidates start declaring their loyalty

CVS is on a mission to consolidate health care. Will it work?

Large hospital system sues Multiplan for low

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

entertainment

hotspot

leisure time

knowledge